WO2003072121A1 - Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient - Google Patents
Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient Download PDFInfo
- Publication number
- WO2003072121A1 WO2003072121A1 PCT/JP2002/006826 JP0206826W WO03072121A1 WO 2003072121 A1 WO2003072121 A1 WO 2003072121A1 JP 0206826 W JP0206826 W JP 0206826W WO 03072121 A1 WO03072121 A1 WO 03072121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glucoside
- cyanidin
- group
- extract
- antiobestic
- Prior art date
Links
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 title claims abstract description 38
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 8
- 229940125708 antidiabetic agent Drugs 0.000 title claims abstract description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 14
- 239000008103 glucose Substances 0.000 claims abstract description 14
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims description 30
- 240000008042 Zea mays Species 0.000 claims description 20
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 20
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 20
- 235000005822 corn Nutrition 0.000 claims description 20
- 241000196324 Embryophyta Species 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 208000008589 Obesity Diseases 0.000 claims description 9
- 235000020824 obesity Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
- 229940039781 leptin Drugs 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 9
- 235000020940 control diet Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000000577 adipose tissue Anatomy 0.000 description 8
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin Natural products [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 8
- 239000003925 fat Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 201000010063 epididymitis Diseases 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 235000007336 cyanidin Nutrition 0.000 description 6
- -1 cyanidin glucosides Chemical class 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 4
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000000274 adsorptive effect Effects 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000005206 Hibiscus Nutrition 0.000 description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101001055216 Homo sapiens Interleukin-9 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102100026871 Interleukin-9 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 241000746966 Zizania Species 0.000 description 1
- 235000002636 Zizania aquatica Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021029 blackberry Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 150000001915 cyanidin derivatives Chemical class 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108700039855 mouse a Proteins 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as an active ingredient and a health food to which cyanidin 3-glucoside or a water-soluble extract from a plant containing cyanidin 3-glucoside is added.
- the sugars and fats after being decomposed by digestive enzymes, are used as an energy source or the like.
- an excess of sugars is changed into fatty acids via acetyl CoA and stored in tissue together with fats, resulting in obesity.
- TNF tumor necrosis factor
- Anthocyanin pigments having a wide distribution in the plant kingdom are used as colorants, but are also known to have an decreasing effect on cholesterol in blood, for example, as bioacitivity (Agric. Biol. Chem., 54(1), 171-175, 1990).
- Cholesterol is a constituent of biological membrane and serum lipoprotein and is synthesized in vivo. Normally, if cholesterol is externally taken, the amount of cholesterol synthesized in vivo is suppressed. However, if a large amount of cholesterol is taken, a cholesterol balance in the body is lost, which results in hypercholesterolemia. Excessive cholesterol causes arterial sclerosis. However, correlation between obesity and cholesterol is not known at present, and the control of cholesterol is not anticipated to lead to the control of weight.
- Japanese Unexamined Patent Application Publication No. 2000-178295 described that cyanidin glucosides have an antitumor effect and that the intake of food containing cyanidin glucosides as active ingredients is preferable for prevention of or amelioration from diseases such as hyperlipidemia, arterial sclerosis, diabetes, fatty liver, myocardial infarction and the like.
- this reference presents pharmacological data supporting only the antitumor effect of the cyanidin glucosides, but does not present any pharmacological data about the antiobestic or antidiabetic effect thereof. It cannot be considered from medical findings that the antitumor effect results in amelioration from obesity or from the above-mentioned diseases.
- cyanidin 3-glucoside suppresses increase of adipose cells and reduces the blood glucose level, to accomplish the present invention.
- the present invention provides an antiobestic and/ or antidiabetic agent containing cyanidin
- 3-glucoside as an active ingredient and a health food to which cyanidin 3-glucoside or a water-soluble extract from a plant containing cyanidin 3-glucoside is added.
- Fig. 1 is a photograph of epididymal adipose tissue of group C ( X 200) in Example 2;
- Fig. 2 is a photograph of epididymal adipose tissue of group A ( X 200) in Example 2
- Fig. 3 is a photograph of epididymal adipose tissue of group H ( X 200) in Example 2;
- Fig. 4 is a photograph of epididymal adipose tissue of group HA ( X 200) in Example 2.
- cyanidin 3-glucoside can be obtained from a plant material, but may be obtained by a semisynthetic or whole synthetic method using a technique known in the field of art.
- cyanidin 3-glucoside may be used one material or two or more materials selected from the group consisting of purple corn, red cabbage, berries such as strawberry, boysenberry, raspberry, cranberry, blackberry and blueberry, grains such as wild rice, red rice, black rice and the like, tamarind, peanut, grape and hibiscus. Any portion of these plants, such as stems, leaves, roots, petals, fruits and seeds, or tissue culture cells thereof may be used.
- cyanidin 3-glucoside from a plant is not particularly limited.
- the plant may be macerated in a warm or cool liquid under an acidic condition adjusted within the range of about pH 1 to pH 4 with use of an inorganic acid such as sulfuric acid or an organic acid such as citric acid, for 4 to 12 hours, for example, overnight to extract a pigment and form a water-soluble extract therefrom.
- the extract may be used as it is or may be filtered and used as filtrate.
- the plant may be used directly or cut or crushed into an appropriate size. Alternatively, dried plants in these various shapes may be used.
- the thus obtained water-soluble extract is thought to contain anthocyanin pigments such as cyanidin 3-glucoside as well as carbohydrates, salt and the like.
- the water-soluble extract may be refined to isolate cyanidin 3-glucoside by combining one or more treatments such as those using ion exchange resins or non-ionic adsorptive resins and filtration or by repeating a single treatment under the same or different conditions.
- a non-ionic adsorptive resin may be used, for example, Duolite S-861 , Duolite S-862, Duolite S-863 or Duolite S-866 of styrene series (trade names manufactured by Diamond Shamrock U.S.A.); Sepabeads SP70, Sepabeads SP700,
- Sepabeads SP825 or Sepabeads SP207 of aromatic series (trade names manufactured by Mitsubishi Chemical Corporation); Diaion HP10, Diaion HP20, Diaion HP21 , Diaion HP40 or Diaion HP50 (trade names manufactured by Mitsubishi Chemical Corporation); Amberlite XAD-4, Amberlite XAD-7 or Amberlite XAD-2000 (trade names manufactured by Organo Corporation) .
- an ion exchange resin may be used as a cation exchange resin, for example, Diaion SK IB, Diaion SK 102, Diaion SK 116, Diaion PK 208, Diaion WK 10 or Diaion WK 20 (trade names manufactured by Mitsubishi Chemical Corporation), and may be used as an anion exchange resin, for example, Diaion SA 10A, Diaion SA 12 A, Diaion SA 20A, Diaion PA 306, Diaion WA 10 or Diaion WA 20 (trade names manufactured by Mitsubishi Chemical Corporation) .
- the filtration may be ultrafiltration or reverse osmosis using various functional polymer membranes.
- cyanidin 3-glucoside obtained by the above-mentioned method suppresses increase of adipose cells and/or reduces the blood glucose level.
- the present invention provides an antiobestic and/ or antidiabetic agent containing cyanidin 3-glucoside or a water-soluble plant extract containing cyanidin 3-glucoside as an active ingredient.
- the agent is manufactured by a conventional method using a solid or liquid excipient known in the art.
- the solid excipients include, for example, lactose, sucrose, glucose, corn starch, gelatin, starch, dextrin, calcium phosphate, calcium carbonate, synthetic and natural aluminum silicate, magnesium oxide, dried aluminum hydroxide, magnesium stearate, sodium bicarbonate, dry yeast and the like.
- the liquid excipients include, for example, water, glycerin, propylene glycol, simple syrup, ethanol, ethylene glycol, polyethylene glycol, sorbitol and the like.
- the above-described agent may contain conventional additives such as stabilizers including citric acid, phosphoric acid, malic acid and salts thereof; sweeteners of high potency including sucralose, acesulfame K and the like, and sweeteners such as sucrose, fructose and the like; preservatives including alcohols, glycerin and the like; demulcentias, diluents, buffers, flavoring agents and coloring agents, if desired.
- the agent may be manufactured into forms for internal use such as dispersion, tablet, emulsion, capsule, granule, chewable tablet, solution, syrup and the like by a conventional method or other suitable method.
- the health food as used in the present invention signifies a food positively intended for health care, health maintenance and health enhancement compared with common food.
- the food added with cyanidin 3-glucoside or the water soluble plant extract containing cyanidin 3-glucoside according to the present invention can be the health food expected to exhibit effects of preventing, treating or ameliorating obesity and/or diabetes.
- the health food used for the above-mentioned purposes can be obtained by mixing or spraying cyanidin 3-glycoside or the water soluble plant extract containing cyanidin 3-glucoside of the invention with or into an intermediate product under processing or a final product, for example, solid, liquid or semisolid products usable itself as food such as starch, wheat flour, sugar and syrup; for example, bread, noodles, sweets including candies and cookies, other solid products; flavor enhancers such as dressings and sauces ; liquid products such as beverage, nutritional drink and soup ; semisolid products such as jerry.
- solid, liquid or semisolid products usable itself as food such as starch, wheat flour, sugar and syrup
- a final product for example, solid, liquid or semisolid products usable itself as food such as starch, wheat flour, sugar and syrup; for example, bread, noodles, sweets including candies and cookies, other solid products; flavor enhancers such as dressings and sauces ; liquid products such as beverage, nutritional drink and soup ; semisolid products such as jerry
- the dose of cyanidin 3-glucoside of the invention is preferably used to an adult of 60 kg in an amount of 10 to 100 mg a day.
- the dose may vary depending on various factors such as health conditions of a person who will take cyanidin 3-glucoside, an administration method and a combination with other agents.
- Cyanidin 3-glucoside of the present invention can be used safely and effectively as a substance for preventing, treating or ameliorating obesity and/or diabetes and, in additional to that, it has the feature of being able to be manufactured economically, because cyanidin 3-glucoside is contained in a lot of species of natural plants and has been used as a food additive.
- the crude extract was subjected to adsorption using 10 L of adsorptive resin (styrene vinyl benzene copolymer; Diaion HP20 manufactured by Mitsubishi Chemical
- the eluate was concentrated under reduced pressure below 40 °C and then was spray-dried to obtain 70 g of a powdered purple corn extract of dark red color.
- This powder contained 18.5 % of cyanidin 3-glucoside.
- the action of cyanidin 3-glucoside was evaluated by adding the extract obtained in Example 1 to a normal diet (control diet) and to a diet containing fats in a higher proportion (high fat diet) .
- mice Four-week old C57BL/6J mice were allocated into four groups (6 to 8 mice per group), which were given the control diet (group C), the control diet + the extract obtained in Example 1 (group A), the high fat diet (group H) and the high fat diet + the extract obtained in Example 1 (group HA), respectively.
- the diets were taken freely for 12 weeks.
- the control diet 1 kg, was composed of 204 g of casein, 35 g of mixed minerals, 10 g of mixed vitamins, 2 g of choline chloride, 50 g of corn oil, 40 g of powered cellulose and 659 g of sucrose.
- the amount of diet taken by each mouse a day was weighed 2, 4, 6, 10 and 12 weeks after the start of dietting the animals (Table 1) .
- group H showed significant increase in weight, BMI and adipose tissue amount as compared with group C, but group HA given the purple corn extract of Example 1 showed significant suppression in weight, BMI and adipose tissue amount. No significant difference was recognized among group C, group A and group HA.
- Glucose concentration, insulin concentration and leptin concentration in serum were measured with Glucose B - Test Kit (manufactured by Wako Junyaku Kogyo), Lbis® Insulin Kit (for mice - T, manufactured by Shibayagi Company) and Leptin Mouse Kit (manufactured by Morinaga Company), respectively (Table 3).
- Table 3 Glucose B - Test Kit (manufactured by Wako Junyaku Kogyo), Lbis® Insulin Kit (for mice - T, manufactured by Shibayagi Company) and Leptin Mouse Kit (manufactured by Morinaga Company), respectively (Table 3).
- Group H was considered to have hyperinsulinemia and hyperleptinemia due to the intake of high fat diet.
- RNAs were extracted from the livers using DNA and RNA extraction reagents and Isogen (manufactured by Nippon Gene) according to the conventional method and were subjected to the RT-PCR to obtain the results shown in Table 4.
- the amount of expressed mRNAs of the fatty acid synthetases was significantly smaller in group A than in group C, and was significantly smaller in group HA than in H. It was confirmed that the synthesis of fatty acids at the molecular level was affected by the purple corn extract of Example 1.
- the amount of expressed mRNAs of leptin was significantly larger in group H than in groups C, A and HA. Correlation between the amount of expressed mRNAs of leptin and the serum leptin concentration was confirmed.
- the purple corn extract containing cyanidin 3-glucoside did not suppress the increase of weight, fat and blood glucose level with regard to the ordinary diet but significantly suppresses it with regard to the high fat diet.
- Example 3 NOD mice which were an I type human diabetes model
- Example 1 (purchased from Clea Japan Inc.) were administered with the extract obtained in Example 1 and the incidence of diabetes was examined.
- mice Six-week-old female NOD mice were allocated into two groups, 16 mice per group, which were given a control diet (pellet CA-1 manufactured by Clea Japan Inc., group NC) and a control diet plus the extract obtained in Example 1 (group NA) for 24 weeks. The diets were taken freely. The incidence of diabetes was observed using dip stick sheets for urinary sugar (Table 5). In group NA, the extract of Example 1 was added so that the content of cyanidin 3-glucoside in the control diet was 0.2 %, and sucrose was deduced from the control diet by the amount of cyanidin 3-glucoside added.
- group NA the extract of Example 1 was added so that the content of cyanidin 3-glucoside in the control diet was 0.2 %, and sucrose was deduced from the control diet by the amount of cyanidin 3-glucoside added.
- Example 2 Using the purple corn extract obtained in Example 1 , materials were blended according to the following formula. The resulting mixture was filtrated, and was put in a 250-mL bottle and was sterilized at 60°C for 20 minutes to prepare a carbonated beverage containing 20 % of grape juice. The beverage, 250 mL, contained about 50 mg of cyanidin 3-glucoside.
- Example 2 Using the purple corn extract obtained in Example 1 , materials were blended according to the following formula, and was prepared into tablets by a tablet machine.
- the cyanidin compound naturally contained in a lot of species of plants can be utilized as antiobestic and/ or antidiabetic agents for suppressing the increase of adipose cells and reducing blood glucose level safely and effectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02745850A EP1480663B1 (en) | 2002-02-28 | 2002-07-04 | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
DE60215866T DE60215866T2 (en) | 2002-02-28 | 2002-07-04 | MEDICAMENT CONTAINING CYANIDINE-3-GLYCOSIDE AS AN ACTIVE AGENT AGAINST FAT SUPPORT AND DIABETES |
US10/504,910 US20050084548A1 (en) | 2002-02-28 | 2002-07-04 | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
CA002477555A CA2477555A1 (en) | 2002-02-28 | 2002-07-04 | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
AU2002317501A AU2002317501A1 (en) | 2002-02-28 | 2002-07-04 | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002054286A JP2003252766A (en) | 2002-02-28 | 2002-02-28 | Antiobesity and/or antidiabetic agent containing cyanidin 3-glucoside as active component |
JP2002-54286 | 2002-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003072121A1 true WO2003072121A1 (en) | 2003-09-04 |
Family
ID=27764391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/006826 WO2003072121A1 (en) | 2002-02-28 | 2002-07-04 | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050084548A1 (en) |
EP (1) | EP1480663B1 (en) |
JP (1) | JP2003252766A (en) |
AT (1) | ATE344049T1 (en) |
AU (1) | AU2002317501A1 (en) |
CA (1) | CA2477555A1 (en) |
DE (1) | DE60215866T2 (en) |
ES (1) | ES2274053T3 (en) |
WO (1) | WO2003072121A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078741A1 (en) * | 2003-03-03 | 2004-09-16 | San-Ei Gen F.F.I., Inc. | Adiponectin expression promoter |
EP1683805A1 (en) * | 2003-10-24 | 2006-07-26 | Meiji Seika Kaisha Ltd. | Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
EP1771188A2 (en) * | 2004-07-29 | 2007-04-11 | Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
EP1773356A2 (en) * | 2004-07-29 | 2007-04-18 | Michigan State University | Insulin secretion by anthocyanins and anthocyanidins |
CN101933919A (en) * | 2010-07-01 | 2011-01-05 | 北京世纪博康医药科技有限公司 | Application of brown cyanidin |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005082390A1 (en) * | 2004-03-02 | 2007-10-25 | アサヒビール株式会社 | Fat accumulation inhibitor |
JP4247833B2 (en) * | 2004-03-16 | 2009-04-02 | 株式会社ケーツーコミュニケーションズ | Visual function improver |
EP1762234A4 (en) * | 2004-06-28 | 2010-05-05 | Kao Corp | Ampk activator |
JP5111725B2 (en) * | 2004-10-21 | 2013-01-09 | 株式会社 バイオセラピー開発研究センター | Pharmaceutical composition using suizenjina |
JP5118292B2 (en) * | 2005-06-16 | 2013-01-16 | 株式会社ロッテ | Lipolysis accelerator |
US20070054965A1 (en) | 2005-09-05 | 2007-03-08 | Kao Corporation | AMPK activating agent |
ITRM20060233A1 (en) * | 2006-04-28 | 2007-10-29 | Angela Maria Amorini | METHOD FOR THE PREPARATION AND USE OF AN ENRICHED CIANIDIN 3 OR BETA GLUCOPYRANOSIDE AND ITS DERIVED EXTRACT FROM FRUITS AND VEGETABLES CONTAINING THE ANTOCIANIN AND FOR THE PURIFICATION AND USE OF CIANIDIN 3 OR BETA GLUCOPYRANOSIS AND ITS DERIVATIVES FROM |
JP5201662B2 (en) * | 2007-02-28 | 2013-06-05 | キッコーマン株式会社 | Blood flow improving composition |
WO2009059218A1 (en) * | 2007-10-31 | 2009-05-07 | Phytomedics, Inc. | Berry preparations for treatment of diabetes and metabolic syndrome |
FI20095144A0 (en) * | 2009-02-17 | 2009-02-17 | Danisco Sugar Oy | food Product |
JP6105186B2 (en) * | 2009-04-22 | 2017-03-29 | 株式会社ブルボン | Pancreatic lipase inhibitor |
KR101322503B1 (en) * | 2010-10-11 | 2013-11-13 | 강원대학교산학협력단 | Composition for Prevention and Treatment of Obesity Comprising Liriope Seed Extracts |
KR101309137B1 (en) | 2011-08-30 | 2013-09-17 | 가톨릭대학교 산학협력단 | Composition for treating diabetic erectile dysfunction comprising C3G or extract of mulberry containing C3G |
JP2016175842A (en) * | 2013-08-12 | 2016-10-06 | オリザ油化株式会社 | Ghg-containing composition, and fat absorption inhibitor using the same |
JP6364362B2 (en) * | 2015-02-17 | 2018-07-25 | 学校法人福岡大学 | Human chymase inhibitor and functional food, and method for inhibiting human chymase activity |
CN114081893A (en) * | 2021-10-11 | 2022-02-25 | 暨南大学 | Application of combined anthocyanin and pectin in preparation of medicine for preventing and/or treating non-alcoholic fatty liver disease |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229439A (en) * | 1977-11-21 | 1980-10-21 | Societe De Recherches Industrielles (Sori) | Method of treatment of atheroma |
EP0815857A1 (en) * | 1995-12-26 | 1998-01-07 | Suntory Limited | Antiobestic agent containing procyanidin as the active ingredient |
JPH11218572A (en) * | 1998-02-04 | 1999-08-10 | Fuji Electric Co Ltd | Ultrasonic sensor |
WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
US20010016573A1 (en) * | 2000-01-28 | 2001-08-23 | Michigan State University, Board Of Trustees Operating | Method for inhibiting a tumor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3334016B2 (en) * | 1994-07-15 | 2002-10-15 | 日研フード株式会社 | Anti-diabetic active substance, anti-diabetic complication active substance and method for producing the same |
JPH09291039A (en) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | Antiobestic medicine comprising procyanidin as active ingredient |
JPH09227398A (en) * | 1996-02-20 | 1997-09-02 | Zeria Pharmaceut Co Ltd | Antiobese agent |
JP2000178295A (en) * | 1998-12-17 | 2000-06-27 | Lion Corp | Antitumor composition |
FR2790645B1 (en) * | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | FOOD SUPPLEMENT AND COSMETIC TREATMENT METHOD BASED ON GRAPE EXTRACT RICH IN POLYPHENOLS |
JP2001046030A (en) * | 1999-08-02 | 2001-02-20 | Tama Seikagaku Kk | Production of blueberry-extracted essence |
JP4549486B2 (en) * | 2000-04-26 | 2010-09-22 | アピ株式会社 | Anti-obesity drug and method for producing the same |
ES2266251T3 (en) * | 2000-08-31 | 2007-03-01 | Phenolics, Llc | EFFECTIVE METHOD FOR PRODUCING ENRICHED COMPOSITIONS WITH ANTOCIANINS. |
-
2002
- 2002-02-28 JP JP2002054286A patent/JP2003252766A/en active Pending
- 2002-07-04 WO PCT/JP2002/006826 patent/WO2003072121A1/en active IP Right Grant
- 2002-07-04 CA CA002477555A patent/CA2477555A1/en not_active Abandoned
- 2002-07-04 US US10/504,910 patent/US20050084548A1/en not_active Abandoned
- 2002-07-04 EP EP02745850A patent/EP1480663B1/en not_active Expired - Lifetime
- 2002-07-04 AT AT02745850T patent/ATE344049T1/en not_active IP Right Cessation
- 2002-07-04 ES ES02745850T patent/ES2274053T3/en not_active Expired - Lifetime
- 2002-07-04 AU AU2002317501A patent/AU2002317501A1/en not_active Abandoned
- 2002-07-04 DE DE60215866T patent/DE60215866T2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229439A (en) * | 1977-11-21 | 1980-10-21 | Societe De Recherches Industrielles (Sori) | Method of treatment of atheroma |
EP0815857A1 (en) * | 1995-12-26 | 1998-01-07 | Suntory Limited | Antiobestic agent containing procyanidin as the active ingredient |
JPH11218572A (en) * | 1998-02-04 | 1999-08-10 | Fuji Electric Co Ltd | Ultrasonic sensor |
WO2001049281A2 (en) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
US20010016573A1 (en) * | 2000-01-28 | 2001-08-23 | Michigan State University, Board Of Trustees Operating | Method for inhibiting a tumor |
Non-Patent Citations (2)
Title |
---|
JOHANSEN O-P ET AL: "CYANIDIN 3-Ä6-(P-COUMAROYL)-2-(XYLOSYL)-GLUCOSIDEÜ-5-GLUCOSIDE AND OTHER ANTHOCYANINS FROM FRUITS OF SAMBUCUS CANADENSIS", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 30, no. 12, 1991, pages 4137 - 4141, XP001120128, ISSN: 0031-9422 * |
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 13 30 November 1999 (1999-11-30) * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078741A1 (en) * | 2003-03-03 | 2004-09-16 | San-Ei Gen F.F.I., Inc. | Adiponectin expression promoter |
EP1683805A1 (en) * | 2003-10-24 | 2006-07-26 | Meiji Seika Kaisha Ltd. | Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
EP1683805A4 (en) * | 2003-10-24 | 2009-06-17 | Meiji Seika Kaisha | Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
EP1771188A2 (en) * | 2004-07-29 | 2007-04-11 | Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
EP1773356A2 (en) * | 2004-07-29 | 2007-04-18 | Michigan State University | Insulin secretion by anthocyanins and anthocyanidins |
EP1773356A4 (en) * | 2004-07-29 | 2010-01-13 | Univ Michigan State | Insulin secretion by anthocyanins and anthocyanidins |
EP1771188A4 (en) * | 2004-07-29 | 2010-04-21 | Univ Michigan State | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
CN101933919A (en) * | 2010-07-01 | 2011-01-05 | 北京世纪博康医药科技有限公司 | Application of brown cyanidin |
Also Published As
Publication number | Publication date |
---|---|
JP2003252766A (en) | 2003-09-10 |
CA2477555A1 (en) | 2003-09-04 |
ES2274053T3 (en) | 2007-05-16 |
DE60215866T2 (en) | 2007-06-21 |
US20050084548A1 (en) | 2005-04-21 |
DE60215866D1 (en) | 2006-12-14 |
ATE344049T1 (en) | 2006-11-15 |
AU2002317501A1 (en) | 2003-09-09 |
EP1480663B1 (en) | 2006-11-02 |
EP1480663A1 (en) | 2004-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1480663B1 (en) | Antiobestic and/or antidiabetic agent containing cyanidin 3-glucoside as active ingredient | |
EP1438964B1 (en) | Process for producing collagen production enhancers and use thereof | |
JP4658348B2 (en) | Collagen production promoter, collagenase inhibitor, fibroblast proliferation agent, elastase inhibitor, estrogen-like agent, and skin cosmetics | |
US20090082285A1 (en) | Adiponectin expression promoter | |
US20070122493A1 (en) | Marine algae extract and glycosidase inhibitor containing the same | |
WO2005112665A1 (en) | Composition containing processed sweet potato foliage | |
EP1325748B1 (en) | Cyanidin mixture for the treatment of large intestine cancer | |
JP4593474B2 (en) | Tyrosinase activity inhibitor and facial blood flow improving agent | |
KR100768830B1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
JP2011055837A (en) | Food and drink for beautification | |
EP1864658A1 (en) | Agent for alleviating vascular insufficiency | |
US20070053929A1 (en) | Marine algae extract and lipase inhibitor containing the same | |
JP2004035510A (en) | Composition for prophylaxis or treatment of diabetes mellitus or its complication | |
WO2007034958A1 (en) | Anti-angiogenic composition comprising grain-derived component as active ingredient | |
JP2008184459A (en) | Calcium absorption accelerating composition | |
EP2156820B1 (en) | Skin whitening agent | |
JP4789453B2 (en) | Anthocyanin absorption promoter | |
KR101398715B1 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus acacia | |
KR100505764B1 (en) | Hangover curing agent containing astaxanthin, aspartic acid and extract from flowers of an arrowroot | |
KR101710276B1 (en) | Composition for anti-diabete comprising ethanol extract of tuna heart | |
US20040053859A1 (en) | Preventive or therapeutic agent for cancer containing cyanidin compound as active ingredient | |
KR20030091178A (en) | Plant extract from Rubus coreanus and composition containing the same with hypoglycemic activity | |
KR101319552B1 (en) | Compositions for prevention or treatment of diabetes mellitus or diabetic complications containing stings of Gleditsia sinensis extracts as an active ingredient | |
RU2317299C2 (en) | Associate containing trehalose and calcium chloride as crystalline monohydrate or anhydrous crystal | |
KR20050006020A (en) | Composition comprising protocathechualdehyde and its pharmaceutically acceptable salt for prevention and treatment of diabetic complication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2477555 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002745850 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10504910 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002745850 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002745850 Country of ref document: EP |